Emzumab 150 mg Injection 1's

Emzumab 150 mg Injection belongs to the class of monoclonal antibodies used to treat various conditions, including allergic asthma, chronic rhinosinusitis (inflammation of the nose and sinuses) with nasal polyps and chronic spontaneous urticaria. Allergic asthma is a type of asthma triggered by allergens, leading to respiratory issues. Chronic rhinosinusitis is a prolonged inflammation of the nasal passages and sinuses, persisting for at least 12 weeks despite treatment. Chronic spontaneous urticaria is defined by recurring episodes of hives and/or angioedema, resulting in itchy, bumpy skin rash and swelling beneath the skin.

Emzumab 150 mg Injection contains Omalizumab, which binds to Immunoglobulin E (IgE), a protein that triggers allergic responses. Emzumab 150 mg Injection blocks IgE from binding to allergens, thereby reducing the severity of allergic reactions and providing relief from symptoms associated with conditions like allergic asthma and chronic spontaneous urticaria.

A healthcare professional will administer Emzumab 150 mg Injection. The common side effects of Emzumab 150 mg Injection include joint pain, dizziness, stomach pain, common cold, headache, ear pain, and injection site reactions, which include pain, swelling, itching, and redness. Most of these adverse effects go away gradually over time on their own. If any of these symptoms worsen or continue, consult a doctor.

Emzumab 150 mg Injection should be avoided if allergic to it or any other components present in it. Before starting Emzumab 150 mg Injection, inform your doctor if you have any liver or kidney disease, autoimmune disease or active parasitic infections. Pregnant and breastfeeding mothers should inform the physician before starting treatment with Emzumab 150 mg Injection. Emzumab 150 mg Injection is not recommended for children under 6 years of age.

Treatment of allergic asthma, chronic rhinosinusitis (inflammation of the nose and sinuses) with nasal polyps and chronic spontaneous urticaria. The detailed uses of Emzumab 150 mg Injection are as follows:

• Moderate to severe allergic asthma: Emzumab 150 mg Injection helps control asthma symptoms when inhaled steroids are insufficient.
• Chronic spontaneous urticaria (hives): Emzumab 150 mg Injection is used to treat chronic spontaneous urticaria when antihistamines fail.
• Nasal polyps: Emzumab 150 mg Injection reduces inflammation and improves breathing.
• Food allergy prevention: Emzumab 150 mg Injection lowers the risk of severe allergic reactions.

• Follow your doctor’s instructions on the dosage and timing of this medication.
• Hold the syringe straight and inject it under the skin, typically in the thigh, abdomen, or upper arm.
• Before administration, ensure that the injection site is clean. Rotate injection sites to reduce discomfort or irritation. Use Emzumab 150 mg Injection only after receiving proper training from the healthcare professional.

Emzumab 150 mg Injection provides significant relief for people with complex allergies. By targeting and neutralizing IgE, Emzumab 150 mg Injection controls inflammation and allergic reactions, improving the quality of life for those with these conditions. It reduces asthma attacks in adults and children above 6 years with moderate to severe allergic asthma. It also effectively manages chronic hives in patients aged 12 years and older by decreasing symptoms. Additionally, Emzumab 150 mg Injection helps adults with chronic rhinosinusitis with nasal polyps who don't respond to nasal steroids.

Emzumab 150 mg Injection should be avoided if allergic to it or any other components present in it. Before starting Emzumab 150 mg Injection, inform your doctor if you have any liver or kidney disease, autoimmune disease or active parasitic infections. Pregnant and breastfeeding mothers should inform the physician before starting treatment with Emzumab 150 mg Injection. Emzumab 150 mg Injection may cause dizziness, so drive only if you are alert and focused. Avoid consuming alcohol along with Emzumab 150 mg Injection as it could lead to increased dizziness. Emzumab 150 mg Injection is not recommended for children under 6 years of age. Emzumab 150 mg Injection is not used to treat acute asthma attacks, hyperimmunoglobulin E syndrome, sudden allergic reactions, food allergies, eczema, and hay fever.